SCHEMBL4371665

SCHEMBL4371665

NCc1ccc2c(c1)C(=O)c1ccc(CC(=O)O)cc1C2=O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 4/20 0.51
MAPT P10636 3/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 2/20 0.46
HPGD P15428 2/20 0.46
HSD17B10 Q99714 2/20 0.46
RGS12 O14924 1/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
APEX1 P27695 1/20 0.46
THPO P40225 1/20 0.46
BLM P54132 1/20 0.46
GNAI1 P63096 1/20 0.46
PMP22 Q01453 1/20 0.46
HIF1A Q16665 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
PSEN1 P49768 1/20 0.45
PSEN2 P49810 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19202482 0.91 AKR1B1 (0.58) AKR1B1MAPTLMNAKDM4EHPGD
SCHEMBL8600926 0.86 AKR1B1 (0.60) AKR1B1MAPTLMNAKDM4EHPGD
SCHEMBL21573719 0.85 NPC1 (0.55) MAPTLMNAGAATSHRTDP1
SCHEMBL14299544 0.84 AKR1B1 (0.58) AKR1B1MAPTLMNAKDM4EHPGD
SCHEMBL9239083 0.81 AKR1B1 (0.53) AKR1B1MAPTLMNAKDM4EHPGD
SCHEMBL16091077 0.81 AKR1B1 (0.58) AKR1B1MAPTLMNAKDM4EHPGD
SCHEMBL9509522 0.80 NPC1 (0.66) MAPTLMNAKDM4EHPGDPOLB
SCHEMBL19202479 0.78 AKR1B1 (0.47) AKR1B1MAPTLMNAKDM4EHPGD
SCHEMBL3803115 0.76 AKR1B1 (0.58) AKR1B1MAPTLMNAKDM4EHPGD
SCHEMBL933080 0.75 CA2 (0.62) AKR1B1MAPTLMNAKDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0573603-A1 INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN CATHEPSIN G Dyax Corp. (US) 1993-12-15 EP claimed
WO-1992015605-A2 INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN CATHEPSIN G PROTEIN ENGINEERING CORPORATION (US) 1992-09-17 WO claimed
EP-1325931-B1 Inhibitors of human neutrophil elastase DYAX CORP (US) 2009-05-13 EP disclosed
US-20030223977-A1 Kunitz domain mutants as cathepsin G inhibitors LEY ARTHUR CHARLES (US) 2003-12-04 US disclosed
EP-1325931-A1 Inhibitors of human neutrophil elastase Dyax Corp. (US) 2003-07-09 EP disclosed
EP-0573603-B1 INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN CATHEPSIN G DYAX CORP (US) 2003-06-25 EP disclosed
EP-0573603-A1 INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN CATHEPSIN G Dyax Corp. (US) 1993-12-15 EP disclosed
WO-1992015605-A2 INHIBITORS OF HUMAN NEUTROPHIL ELASTASE AND HUMAN CATHEPSIN G PROTEIN ENGINEERING CORPORATION (US) 1992-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030223977-A1 Kunitz domain mutants as cathepsin G inhibitors CTSG, SPINT2, CTSZ AKR1B1 3853/4885MAPT 4272/4885LMNA 2809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.